Targeting mesothelin receptors with drug-loaded bacterial nanocells suppresses human mesothelioma tumour growth in mouse xenograft models-Reference-Cited by-同舟云学术

Targeting mesothelin receptors with drug-loaded bacterial nanocells suppresses human mesothelioma tumour growth in mouse xenograft models

Published:2017-10-23 Issue:10 Volume:12 Page:e0186137
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Alfaleh Mohamed A.,Howard Christopher B.^ORCID,Sedliarou Ilya,Jones Martina L.,Gudhka Reema,Vanegas Natasha,Weiss Jocelyn,Suurbach Julia H.,de Bakker Christopher J.,Milne Michael R.,Rumballe Bree A.,MacDiarmid Jennifer A.,Brahmbhatt Himanshu,Mahler Stephen M.

Funder

Australian Research Council

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference63 articles.

1. Natural history and epidemiology of malignant mesothelioma;KH Antman;Chest,1993

2. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial;MF Muers;Lancet,2008

3. Asbestos bodies and mesothelioma;J Stumphius;The Annals of occupational hygiene,1968

4. Cellular and molecular mechanisms of asbestos carcinogenicity: implications for biopersistence;JC Barrett;Environmental health perspectives,1994

5. The pathogenesis of mesothelioma;M Carbone;Seminars in diagnostic pathology,2006

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Specific Targeting of Mesothelin-Expressing Malignant Cells Using Nanobody-Functionalized Magneto-Fluorescent Nanoassemblies;International Journal of Nanomedicine;2024-01

2. Long-term, in vivo therapeutic effects of a single dose of miR-145 micelles for atherosclerosis;Bioactive Materials;2023-09

3. Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: A review;Journal of Controlled Release;2023-07

4. Engineered bacterial membrane vesicles are promising carriers for vaccine design and tumor immunotherapy;Advanced Drug Delivery Reviews;2022-07

5. Silencing VDAC1 to Treat Mesothelioma Cancer: Tumor Reprograming and Altering Tumor Hallmarks;Biomolecules;2022-06-27